Contents: Deep Dive – Market Access

Market Access Cover
Cover

Market Access

Click here

Market Access Introduction
Introduction

Welcome from the Editor

Click here

Janssen: ‘Open dialogue’ needed with HTAs to improve access
Janssen: ‘Open dialogue’ needed with HTAs to improve access

The traditional ways of assessing drugs may no longer be fit for purpose. Janssen’s Martin Price says that the only way forward is better collaboration with HTAs

Click here

Market access in the time of COVID-19
Market access in the time of COVID-19

COVID-19 has left no part of life untouched, including HTA and other payer agencies activities, and it will likely have a lasting impact on market access.  Leela Barham takes stock and looks ahead

Click here

The pharma world at your fingertips
The pharma world at your fingertips

Daily News from pharmaphorum – insights and analysis on the big trends shaping healthcare and the pharmaceutical industry

Click here

Breaking policy and perceptual barriers Biosimilars
Breaking policy and perceptual barriers: Biosimilars

How policy impacts biosimilar adoption and what strategies manufacturers should consider to optimise success

Click here

A novel approach to detecting Alzheimer’s early
A novel approach to detecting Alzheimer’s, early

The grey matter in the brain may hold vital clues for early, accurate detection in Alzheimer’s disease

Click here

6 ways to digitise your business at pace
6 ways to digitise your business at pace

For decades, pharma companies have prioritised face to face contact – but now is the time to realise the multi-channel opportunity

Click here

Improving access and reimbursement for specialty therapies
Improving access and reimbursement for specialty therapies

Several executives from ICON share their thoughts on how clinical development can better satisfy the evidence needs of HTAs and payers

Click here

Podcast

Listen to discussions of key industry trends with leading pharma figures

Click here

Eyeforpharma 2020 Redefining-value-for COVID-19 and beyond
Eyeforpharma 2020: Redefining value for COVID-19 and beyond

We look at some of the key market access insights from this year’s eyeforpharma Barcelona and Philadelphia virtual meetings

Click here

How pharma can adapt to online engagement in a post COVID-19 world
How pharma can adapt to online engagement post-COVID-19

Virtual engagement is now a necessity for pharma rather than a nice-to-have – and it seems likely these changes will be here to stay

Click here

Breaking barriers to patient access
Breaking barriers to patient access in rare oncology

Some cancers are now being redefined as rare diseases. OPEN VIE explores the challenges in ensuring innovation reaches everyone that needs it

Click here

The need for digital transformation and a response model for COVID-19
Digital health and pharma – adapting to the post-coronavirus paradigm

The need for digital transformation and a response model for COVID-19

Click here

Market Access future editions
Forthcoming issues of Deep Dive

Sign up to receive complimentary editions of the magazine direct to your inbox, including the forthcoming Oncology issue

Click here

Market Access Contact
Deep Dive – contact us

How to get in touch with the magazine’s editorial, commercial and design teams

Click here

Video
Share

Your name

Your e-mail

Name receiver

E-mail address receiver

Your message

Send

Share

E-mail

Facebook

Twitter

LinkedIn

Contact

Send